CNTB (Connect Biopharma Holdings) Net Margin %: -11,478.11% (As of Mar. 2026)


CNTB Connect Biopharma Holdings Ltd CNTB
7 GF Score
Price $2.13
! 3 Warning Signs
View Full Analysis

What is Connect Biopharma Holdings Net Margin %?

Connect Biopharma Holdings CNTB +1.44% 7 Net Margin % is -11,478.11% as of Mar. 2026. GuruFocus rates CNTB with a GF Score™ of 7/100. The stock has 3 warning signs investors should review. Among 947 Biotechnology companies, Connect Biopharma Holdings ranks worse than 96.09% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Connect Biopharma Holdings's Net Income for the three months ended in Mar. 2026 was $-19.40 Mil. Connect Biopharma Holdings's Revenue for the three months ended in Mar. 2026 was $0.17 Mil. Therefore, Connect Biopharma Holdings's net margin for the quarter that ended in Mar. 2026 was -11,478.11%.

The historical rank and industry rank for Connect Biopharma Holdings's Net Margin % or its related term are showing as below:

CNTB' s Net Margin % Range Over the Past 10 Years
Min: -86687.5   Med: -43373.77   Max: -60.03
Current: -27727.9

CNTB's Net Margin % is ranked worse than
96.09% of 947 companies
in the Biotechnology industry
Industry Median: -89.33 vs CNTB: -27727.90

Connect Biopharma Holdings  (NAS:CNTB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Connect Biopharma Holdings Net Margin % Related Terms

Connect Biopharma Holdings Net Margin % Historical Data

* Premium members only.

The historical data trend for Connect Biopharma Holdings's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Connect Biopharma Holdings Net Margin % Chart

Connect Biopharma Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 -60.03 -86,687.50

Connect Biopharma Holdings Quarterly Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -26,872.92 -107,500.00 0.00 -11,478.11

CNTB vs ANTX, VXRT, TTRX: Net Margin % Comparison

For the Biotechnology subindustry, Connect Biopharma Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Connect Biopharma Holdings Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Connect Biopharma Holdings's Net Margin % distribution charts can be found below:

* The bar in red indicates where Connect Biopharma Holdings's Net Margin % falls into.


CNTB
7GF Score
Connect Biopharma Holdings Ltd CNTB
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Connect Biopharma Holdings Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Connect Biopharma Holdings's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-55.48/0.064
=-86,687.50 %

Connect Biopharma Holdings's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-19.398/0.169
=-11,478.11 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -11,478.11% mean?
Connect Biopharma Holdings (CNTB) has a Net Margin % of -11,478.11% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Connect Biopharma Holdings and its competitors. According to the industry distribution chart, Connect Biopharma Holdings ranks #910 out of 947 companies in the Biotechnology industry, placing it in the top 96.1%.
Is Connect Biopharma Holdings' Net Margin % too high?
Connect Biopharma Holdings' current Net Margin % is -11,478.11%. Based on the distribution chart, Connect Biopharma Holdings ranks #910 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Connect Biopharma Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Connect Biopharma Holdings' Net Margin % compare to ANTX and VXRT?
According to the Biotechnology industry distribution chart, Connect Biopharma Holdings ranks #910 out of 947 companies for Net Margin %. This places Connect Biopharma Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Connect Biopharma Holdings and its competitors. Connect Biopharma Holdings's current Net Margin % is -11,478.11%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Connect Biopharma Holdings stock overvalued right now?
Connect Biopharma Holdings (CNTB) has a current Net Margin % of -11,478.11%. The current Net Margin % is -11,478.11%. Connect Biopharma Holdings' overall GF Score™ is 7/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Connect Biopharma Holdings (CNTB), the current Net Margin % is -11,478.11% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Connect Biopharma Holdings Business Description

Address 3580 Carmel Mountain Road, Suite 200, San Diego, CA, USA, 92130
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
7GF Score

Get the complete analysis for CNTB

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.13
Price